XE 991 dihydrochloride

Research use only, not for human use.

A potent, selective and orally active blocker of voltage-gated potassium channels Kv7 (KCNQ) that blocks KCNQ1, KCNQ2 and KCNQ2+KCNQ3 with Kd of 0.78, 0.7 and 0.6 uM, respectively.

A potent, selective and orally active blocker of voltage-gated potassium channels Kv7 (KCNQ) that blocks KCNQ1, KCNQ2 and KCNQ2+KCNQ3 with Kd of 0.78, 0.7 and 0.6 uM, respectively; displays 14-fold less potency for KCNQ1+minK current with Kd of 11 uM, enhances hippocampal ACh release from rat brain slices (EC50=490 nM) and is a cognitive enhancer in vivo.Alzheimer Disease Discontinued.

XE991 dihydrochloride possesses an EC50 of 490 nM for enhancement of [3H]ACh release from rat brain slices, and shows good in vivo potency and duration of action.

——

XE-991 | XE991

Cell Cycle/DNA Damage

Potassium Channel

Potassium Channel

Neurological Disease

Alzheimer Disease

122955-13-9

449.37

C26H20N2O.2HCl

>98% (HPLC)

In Vitro:?H2O : 11.11 mg/mL (24.72 mM)

O=C1C2=C(C=CC=C2)C(CC3=CC=NC=C3)(CC4=CC=NC=C4)C5=CC=CC=C15

10,10-bis(4-Pyridinylmethyl)-9(10H)-anthracenone dihydrochloride

(-20℃)

With Ice Pack

≥ 2 years